# A negative DPYD screen is not a complete toxicity forecast

A report can say that the tested DPYD variants were not found without saying that every cause of treatment toxicity has been excluded. Those sentences sound similar when compressed into “negative”. They have different meanings, and the distinction is worth preserving before the report reaches a consultation.

DPYD is the gene associated with the enzyme dihydropyrimidine dehydrogenase, usually shortened to DPD. A gene test and an assessment of enzyme deficiency are connected, but the names should not be used interchangeably. The [MHRA’s fluoropyrimidine safety update](https://www.gov.uk/drug-safety-update/5-fluorouracil-intravenous-capecitabine-tegafur-dpd-testing-recommended-before-initiation-to-identify-patients-at-increased-risk-of-severe-and-fatal-toxicity) describes pre-treatment testing and explicitly warns that a negative result does not remove the possibility of severe toxicity.

## What did “negative” refer to?

In a fictional example, Ellis receives a short letter saying “DPYD normal”. The original laboratory page says “none of the variants tested detected”. Ellis copies the original wording into a question for the oncology team: “Which variants were included, and what does this result leave untested?” No genotype is inferred from the shorthand letter.

That question has a concrete purpose. A targeted panel searches a defined set of variants. It is not automatically a comprehensive assessment of every relevant change in the gene. A reader does not need to memorise the variant list, but should be able to find it or ask where it is recorded. A negative result belongs to the test’s scope.

The MHRA update distinguishes genetic and phenotypic approaches. A phenotypic assessment concerns a measured biological characteristic, whereas genotyping concerns specified DNA variation. One should not silently replace the other in a personal record. Write the actual test type, sample date and laboratory wording instead of turning every result into “DPD passed”.

## Keep the route and medicine attached

The [EMA’s regulatory referral](https://www.ema.europa.eu/en/medicines/human/referrals/fluorouracil-fluorouracil-related-substances-capecitabine-tegafur-flucytosine-containing-medicinal-products) addresses fluorouracil and related medicines within defined treatment contexts. A recommendation about systemic treatment should not be casually transferred to every preparation sharing part of a medicine name.

For example, a person searching a leaflet may find information about an intravenous medicine and assume it describes a topical product. The useful response is to identify the exact product and route, then use the corresponding professional advice. A gene heading on an internet page does not erase differences between formulations or clinical uses.

This article deliberately does not provide treatment choices or dose reductions. Those require a clinical team, the actual result and the applicable pathway. Report literacy helps you understand what information that team is using; it does not make the information sufficient for self-management.

## Screening and monitoring answer different questions

The [CPIC DPYD guideline publication](https://pmc.ncbi.nlm.nih.gov/articles/PMC5760397/) describes interpretation of genetic information for fluoropyrimidines. Its indexed abstract was accessible in this research session; the full manuscript page was blocked. We do not claim to have inspected its current supplementary tables or every subsequent update.

A pre-treatment result is one part of a process, not a forecast of every experience during treatment. Monitoring and symptom instructions remain relevant after testing. A report cannot notice a new symptom or determine whether it is expected, urgent or unrelated. That assessment belongs with the treating service and its safety instructions.

In the fictional appointment, Ellis asks for the team’s contact route and where treatment-specific symptom advice is written. Ellis does not wait for a genetic report to validate a concern. This keeps the laboratory result and the practical safety plan in their proper roles: one describes tested information; the other explains what to do during care.

## Keep a precise record, not a reassuring slogan

A useful saved note has the test name, whether it was genotyping or another assessment, the variants or coverage description, the exact result and the team’s explanation of its limitations. If the coverage is missing, mark it unknown. Do not infer a broad “no risk” label from a short negative statement.

At the next discussion, ask who holds the complete report and whether the result has been recorded in the treatment record. Those questions address communication, not a demand for a particular additional test. The team can explain whether anything else is relevant to the specific treatment setting.

The takeaway is to expand the word “negative” back into its original sentence. That sentence usually tells you what was looked for. Keeping its boundary visible makes the result more useful and avoids promising a kind of protection the test did not provide.

## Scope and source access

Research accessed 4 October 2026: official MHRA and EMA indexed regulatory text and the CPIC publication’s indexed abstract. Access to the full CPIC manuscript was blocked. No patient toxicity estimate, test-selection decision or medication adjustment is supplied. Follow the treating service’s existing symptom and urgent-contact instructions.